enVVeno Medical Corporati... (NVNO)
| Bid | 3.48 |
| Market Cap | 70.32M |
| Revenue (ttm) | 812K |
| Net Income (ttm) | -21.33M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -3.4 |
| Forward PE | -4.14 |
| Analyst | n/a |
| Ask | 4.1 |
| Volume | 97,826 |
| Avg. Volume (20D) | 101,654 |
| Open | 4.22 |
| Previous Close | 4.13 |
| Day's Range | 3.94 - 4.22 |
| 52-Week Range | 2.03 - 6.48 |
| Beta | 0.92 |
About NVNO
undefined
1 month ago · accessnewswire.com
enVVeno Medical Appoints Jennifer Bright as Chief Financial OfficerIRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, ...
1 month ago · accessnewswire.com
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular SurgeryPromising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous comp...
1 month ago · accessnewswire.com
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumIRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
2 months ago · accessnewswire.com
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentModerated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasda...
